Yuta Kubota1, Kazuhiro Tanaka2, Masanori Hisaoka3, Tsutomu Daa4, Tatsuya Iwasaki1, Masanori Kawano1, Ichiro Itonaga1, Hiroshi Tsumura1. 1. Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka Hasama, 879-5593, Yufu City, Oita, Japan. 2. Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka Hasama, 879-5593, Yufu City, Oita, Japan. ktanaka@oita-u.ac.jp. 3. Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, 807-8555, Kitakyushu, Japan. 4. Department of Diagnostic Pathology, Faculty of Medicine, Oita University, 1-1 Idaigaoka Hasama, 879-5593, Yufu City, Oita, Japan.
Abstract
BACKGROUND: It is very rare for clear cell sarcomas (CCS) to arise in the bone. During diagnosis, it is important to distinguish primary CCS of bone from bone metastasis of melanoma because this difference fundamentally changes the therapeutic options. Recently, characteristic fusion genes of CCS have been detected using reverse transcription polymerase chain reaction (RT-PCR) or direct sequencing which allowed to distinguish CCS from melanoma. However, there was no study applying these analyses with positive results. In this case, we describe the use of fusion gene analysis to diagnose a primary CCS of the bone. CASE PRESENTATION: A 36-year-old male presented with a four-months history of left knee pain. Magnetic resonance imaging showed a lesion in the left femoral medial epicondyle. Histological examination of the biopsy specimen revealed proliferating oval or rounded cells. These cells had clear cytoplasm arranged in fascicles or compact nests with frequent deposits of brown pigment. Furthermore, immunohistochemistry analysis revealed that tumor cells were positive for S-100 protein, HMB-45, Melan-A, and SOX10. It stained negative for CD34 and BRAF v600e. Conclusively, detection of the EWSR1/ATF1 fusion gene using RT-PCR and direct sequencing confirmed that the lesion was a primary CCS of the bone. Wide-margin resection and reconstruction with a tumor endoprosthesis were performed. CONCLUSIONS: Herein, we diagnosed a rare case of primary CCS of the bone by detecting EWSR1/ATF1 fusion gene using RT-PCR and direct sequencing. Since fluorescence-in situ hybridization (FISH) and RT-PCR could show false positive by mainly due to technical problems, it is better to perform direct sequencing to confidently diagnose the tumor as a primary CCS especially at very rare site such as bone.
BACKGROUND: It is very rare for clear cell sarcomas (CCS) to arise in the bone. During diagnosis, it is important to distinguish primary CCS of bone from bone metastasis of melanoma because this difference fundamentally changes the therapeutic options. Recently, characteristic fusion genes of CCS have been detected using reverse transcription polymerase chain reaction (RT-PCR) or direct sequencing which allowed to distinguish CCS from melanoma. However, there was no study applying these analyses with positive results. In this case, we describe the use of fusion gene analysis to diagnose a primary CCS of the bone. CASE PRESENTATION: A 36-year-old male presented with a four-months history of left knee pain. Magnetic resonance imaging showed a lesion in the left femoral medial epicondyle. Histological examination of the biopsy specimen revealed proliferating oval or rounded cells. These cells had clear cytoplasm arranged in fascicles or compact nests with frequent deposits of brown pigment. Furthermore, immunohistochemistry analysis revealed that tumor cells were positive for S-100 protein, HMB-45, Melan-A, and SOX10. It stained negative for CD34 and BRAF v600e. Conclusively, detection of the EWSR1/ATF1 fusion gene using RT-PCR and direct sequencing confirmed that the lesion was a primary CCS of the bone. Wide-margin resection and reconstruction with a tumor endoprosthesis were performed. CONCLUSIONS: Herein, we diagnosed a rare case of primary CCS of the bone by detecting EWSR1/ATF1 fusion gene using RT-PCR and direct sequencing. Since fluorescence-in situ hybridization (FISH) and RT-PCR could show false positive by mainly due to technical problems, it is better to perform direct sequencing to confidently diagnose the tumor as a primary CCS especially at very rare site such as bone.
Entities:
Keywords:
Clear cell sarcoma; Direct sequencing; Fusion gene; Melanoma; Primary bone tumor; Reverse transcription polymerase chain reaction
Authors: Maria A Pletneva; Aleodor Andea; Nallasivam Palanisamy; Bryan L Betz; Shannon Carskadon; Min Wang; Rajiv M Patel; Douglas R Fullen; Paul W Harms Journal: Arch Pathol Lab Med Date: 2014-10 Impact factor: 5.534
Authors: Leo Lin; John Carlquist; Will Sinclair; Tara Hall; Bert K Lopansri; Sterling T Bennett Journal: Arch Pathol Lab Med Date: 2021-03-01 Impact factor: 5.534
Authors: Ian J Davis; Jessica J Kim; Fatih Ozsolak; Hans R Widlund; Orit Rozenblatt-Rosen; Scott R Granter; Jinyan Du; Jonathan A Fletcher; Christopher T Denny; Stephen L Lessnick; W Marston Linehan; Andrew L Kung; David E Fisher Journal: Cancer Cell Date: 2006-06 Impact factor: 31.743
Authors: Cristina R Antonescu; Khedoudja Nafa; Neil H Segal; Paola Dal Cin; Marc Ladanyi Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: M Isabel Gonzaga; Leah Grant; Christina Curtin; Jonathan Gootee; Peter Silberstein; Elida Voth Journal: J Cancer Res Clin Oncol Date: 2018-06-30 Impact factor: 4.553
Authors: O Hocar; A Le Cesne; S Berissi; P Terrier; S Bonvalot; D Vanel; A Auperin; C Le Pechoux; B Bui; J M Coindre; C Robert Journal: Dermatol Res Pract Date: 2012-05-30